Literature DB >> 25259411

Tc17 Cells in Immunity and Systemic Autoimmunity.

Yan Liang1, Hai-Feng Pan, Dong-Qing Ye.   

Abstract

Tc17 cells-a subset of CD8(+)T cells-have recently been identified that are characterized by the production of interleukin (IL)-17. Cytokines IL-6 and transforming growth factor-beta 1 (TGF-β1) and transcription factors signaling transducers and activators of transcription (STAT)3, retinoic acid receptor-related orphan nuclear receptor gamma (RORγt), and interferon regulatory factor (IRF)4 are necessary for differentiation of Tc17 cells, controlling expression of molecules essential for Tc17 cell trafficking and function. Current human researches have determined the significance of CD161 expression as either a marker of Tc17 cells or as an effector and regulator of Tc17 cell function. Noncytotoxic Tc17 cells possess a high plasticity to convert into IFN-γ producing cells, which exhibit strong cytotoxic activity. The importance of in vivo plasticity of Tc17 cells for the induction of autoimmune diseases has been demonstrated and Tc17 cells potentially represent novel therapeutic targets in autoimmune diseases. The involvement of interleukin (IL)-17-producing CD8(+)T cells (Tc17) in various conditions, such as infection, cancer, and autoimmune inflammation, has been documented in both humans and mice; however, Tc17 cells have received only marginal attention. Here, we provide an overview of the cytokines and chemokines that characterize the murine and human Tc17 cells. Moreover, we discuss signaling pathways, molecular interactions, and transcriptional events that contribute to Tc17 differentiation and acquisition of effector functions. Also considered is the basis of Tc17 cell plasticity toward the Tc1 lineage, and we suggest that in vivo plasticity of Tc17 cells may be a key feature of Tc17 cell biology in autoimmune diseases. Furthermore, current human researches have revealed that Tc17 cells are different than that in mice because all of them express CD161 and exclusively originate from CD161 precursors present in umbilical cord blood. Finally, we focus on the recent evidence for long-lived Tc17 memory cell populations in mouse models and humans, and their functional roles in mediating disease memory. Hopefully, the information obtained will benefit for developing novel therapeutic strategies.

Entities:  

Keywords:  CD8+T cell; autoimmune diseases; immunity; interleukin-17

Mesh:

Substances:

Year:  2014        PMID: 25259411     DOI: 10.3109/08830185.2014.954698

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN: 0883-0185            Impact factor:   5.311


  25 in total

Review 1.  A literature review on the patients with autoimmune diseases following vaccination against infections.

Authors:  Yan Liang; Fan-Ya Meng; Hai-Feng Pan; Dong-Qing Ye
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  The proportion of different interleukin-17-producing T-cell subsets is associated with liver fibrosis in chronic hepatitis C.

Authors:  Fabio C O F Cachem; Aleida S Dias; Clarice Monteiro; José Roberto Castro; Gabriel Fernandes; Letícia Delphim; Adilson J Almeida; Felipe Tavares; Alessandra M A Maciel; Marcia M Amendola-Pires; Carlos E Brandão-Mello; Cleonice A M Bento
Journal:  Immunology       Date:  2017-03-13       Impact factor: 7.397

3.  CD8+ T cells produce a dialyzable antigen-specific activator of dendritic cells.

Authors:  Ian A Myles; Ming Zhao; Glenn Nardone; Lisa R Olano; Jensen D Reckhow; Danial Saleem; Timothy J Break; Michail S Lionakis; Timothy G Myers; Paul J Gardina; Charles H Kirkpatrick; Steven M Holland; Sandip K Datta
Journal:  J Leukoc Biol       Date:  2016-08-11       Impact factor: 4.962

4.  Fumarates target the metabolic-epigenetic interplay of brain-homing T cells in multiple sclerosis.

Authors:  Achilles Ntranos; Vasilis Ntranos; Valentina Bonnefil; Jia Liu; Seunghee Kim-Schulze; Ye He; Yunjiao Zhu; Rachel Brandstadter; Corey T Watson; Andrew J Sharp; Ilana Katz Sand; Patrizia Casaccia
Journal:  Brain       Date:  2019-03-01       Impact factor: 13.501

Review 5.  Beyond the TNF-α Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology.

Authors:  Susanne Juhl Pedersen; Walter P Maksymowych
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

6.  Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy.

Authors:  Melissa G Lechner; Mandy I Cheng; Anushi Y Patel; Aline T Hoang; Natalie Yakobian; Michael Astourian; Marissa S Pioso; Eduardo D Rodriguez; Ethan C McCarthy; Willy Hugo; Trevor E Angell; Alexandra Drakaki; Antoni Ribas; Maureen A Su
Journal:  J Immunol       Date:  2022-07-11       Impact factor: 5.426

7.  IL-17A-producing T cells are associated with the progression of lung adenocarcinoma.

Authors:  Zhang Bao; Guohua Lu; Dawei Cui; Yinan Yao; Guangdie Yang; Jianying Zhou
Journal:  Oncol Rep       Date:  2016-05-27       Impact factor: 3.906

8.  Stimulation with Concanavalin-A Induces IL-17 Production by Canine Peripheral T Cells.

Authors:  Michelle G Ritt; Beth A Lindborg; Timothy D O'Brien; Joseph Bisignano; Jaime F Modiano
Journal:  Vet Sci       Date:  2015-04-10

9.  The role of soluble tumor necrosis factor like weak inducer of apoptosis and interleukin-17A in the etiopathogenesis of celiac disease: A cross-sectional study.

Authors:  Mahmut Yuksel; Mustafa Kaplan; Ihsan Ates; Zeki Mesut Yaln Kilic; Hasan Kilic; Nuretdin Suna; Hale Ates; Ertugrul Kayacetin
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

10.  Loss of Tff1 Promotes Pro-Inflammatory Phenotype with Increase in the Levels of RORγt+ T Lymphocytes and Il-17 in Mouse Gastric Neoplasia.

Authors:  Mohammed Soutto; Mohamed Saleh; Mohamed S Arredouani; Blanca Piazuelo; Abbes Belkhiri; Wael El-Rifai
Journal:  J Cancer       Date:  2017-07-22       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.